Scopus Biopharma Inc. (SCPS)

Overview

Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapeutics aimed at addressing severe diseases that currently have unmet medical needs. With a focus on transforming patient care, the company leverages advanced technologies to create solutions that can dramatically enhance health outcomes. Scopus BioPharma operates under a strong commitment to research and development, ensuring that their process from discovery to clinical trials is rooted in scientific excellence and strategic partnerships. This dedication is evident in their collaborations with renowned institutions such as the City of Hope, the National Institutes of Health Program, and The Hebrew University of Jerusalem. Initially established as Project18 Inc., the company underwent a rebranding to Scopus BioPharma Inc. in December 2017, marking a new chapter in its journey towards pioneering healthcare solutions. Headquartered in New York, New York, Scopus BioPharma continues to push the boundaries of medicine, striving to make significant contributions to the field of biopharmaceuticals.

Products and Services

Scopus BioPharma Inc. has developed an innovative portfolio, centered around its Duet Platform, a cutting-edge therapeutic approach designed to activate the body’s immune response against cancer. Below are key developments:

• Duet Platform:

  This foundational technology combines the potent effects of STAT3, a master immune checkpoint inhibitor, and TLR9, to construct a set of bifunctional oligonucleotides. These oligonucleotides are engineered to activate antigen-presenting cells within the tumor microenvironment, thereby reducing tumor immunosuppression and initiating T cell-driven immune responses. The Duet Platform serves as the base for a series of products, including:

  • CpG-STAT3ASO (DUET-02): Targeting systemic diseases for the treatment of solid tumors such as prostate and kidney cancers through systemic delivery.
  • CpG-STAT3siRNA (DUET-01): Being developed as a monotherapy, this product primarily focuses on combatting B-cell non-Hodgkin lymphoma.
  • CpG-STAT3decoy (DUET-03): Specifically targets the STAT3 transcription factor protein itself, offering a novel approach in the fight against cancer.